# Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.

> **NCT00729599** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 31 (actual)

## Conditions studied

- Hygiene

## Interventions

- **DRUG:** Cetylpyridinium chloride

## Key facts

- **NCT ID:** NCT00729599
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2009-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729599, "Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*